NasdaqCM - Delayed Quote • USD
Vaxart, Inc. (VXRT)
At close: May 17 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.14 | -0.12 | -0.45 | -0.41 |
| Low Estimate | -0.16 | -0.16 | -0.61 | -0.61 |
| High Estimate | -0.12 | -0.09 | -0.32 | -0.19 |
| Year Ago EPS | -0.16 | -0.11 | -0.57 | -0.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 50k | 1.42M | 15.47M | 23.1M |
| Low Estimate | -- | -- | 2.2M | -- |
| High Estimate | 150k | 4.1M | 39.1M | 64.3M |
| Year Ago Sales | 80k | -- | 7.38M | 15.47M |
| Sales Growth (year/est) | -37.50% | -- | 109.60% | 49.30% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.18 | -0.18 | -0.14 | -0.14 |
| EPS Actual | -0.16 | -0.11 | -0.12 | -0.14 |
| Difference | 0.02 | 0.07 | 0.02 | 0 |
| Surprise % | 11.10% | 38.90% | 14.30% | 0.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.14 | -0.12 | -0.45 | -0.41 |
| 7 Days Ago | -0.14 | -0.12 | -0.45 | -0.39 |
| 30 Days Ago | -0.14 | -0.12 | -0.45 | -0.39 |
| 60 Days Ago | -0.13 | -0.13 | -0.48 | -0.43 |
| 90 Days Ago | -0.13 | -0.14 | -0.49 | -0.42 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | 1 |
Growth Estimates
| CURRENCY IN USD | VXRT | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 12.50% | -- | -- | 8.00% |
| Next Qtr. | -9.10% | -- | -- | 12.40% |
| Current Year | 21.10% | -- | -- | 5.60% |
| Next Year | 8.90% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.14% |
| Past 5 Years (per annum) | -35.45% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Upgrade | B. Riley Securities: Neutral to Buy | 1/31/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 9/7/2023 |
| Maintains | Cantor Fitzgerald: Overweight to Overweight | 8/7/2023 |
| Maintains | B. Riley Securities: Neutral | 12/19/2022 |
| Maintains | Cantor Fitzgerald: Overweight | 9/2/2022 |
| Maintains | B. Riley Securities: Neutral | 5/19/2022 |
Related Tickers
INO Inovio Pharmaceuticals, Inc.
12.00
-6.18%
OCGN Ocugen, Inc.
1.9100
-3.54%
SRNE Sorrento Therapeutics, Inc.
0.0002
-98.33%
NVAX Novavax, Inc.
12.99
-9.79%
ACIU AC Immune SA
3.1800
-6.74%
JAGX Jaguar Health, Inc.
0.2585
-9.84%
IBIO iBio, Inc.
1.9800
+9.39%
SCPX Scorpius Holdings, Inc.
0.1035
+3.40%
ALT Altimmune, Inc.
8.01
-10.00%
SAVA Cassava Sciences, Inc.
23.12
+7.24%